These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 26717884)

  • 1. Cost-effectiveness and cost-utility analysis of OTC use of simvastatin 10 mg for the primary prevention of myocardial infarction in Iranian men.
    Amirsadri M; Hassani A
    Daru; 2015 Dec; 23():56. PubMed ID: 26717884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men.
    Peura P; Martikainen J; Soini E; Hallinen T; Niskanen L
    Curr Med Res Opin; 2008 Jun; 24(6):1823-32. PubMed ID: 18485270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost-effectiveness and cost-utility analysis of the use of enoxaparin compared with heparin for venous thromboembolism prophylaxis in medical inpatients in Iran.
    Amirsadri M; Mousavi S; Karimipour A
    Daru; 2019 Dec; 27(2):627-634. PubMed ID: 31368091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of Simvastatin Plus Ezetimibe for Cardiovascular Prevention in Patients With a History of Acute Coronary Syndrome: Analysis of Results of the IMPROVE-IT Trial.
    Almalki ZS; Guo JJ; Alahmari A; Alotaibi N; Thaibah H
    Heart Lung Circ; 2018 Jun; 27(6):656-665. PubMed ID: 28716519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term Cost-effectiveness of Statin Treatment for Primary Prevention of Cardiovascular Disease in the Elderly.
    Lin L; Teng M; Zhao YJ; Khoo AL; Seet RC; Yong QW; Yeo TC; Lim BP
    Cardiovasc Drugs Ther; 2015 Apr; 29(2):187-97. PubMed ID: 25860556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of a cardiovascular disease primary prevention programme in a primary health care setting. Results of the Polish part of the EUROACTION project.
    Sović N; Pająk A; Jankowski P; Duenas A; Kawecka-Jaszcz K; Wolfshaut-Wolak R; Stepaniak U; Kawalec P
    Kardiol Pol; 2013; 71(7):702-11. PubMed ID: 23907903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness evaluation of aspirin in primary prevention of myocardial infarction amongst males with average cardiovascular risk in Iran.
    Amirsadri M; Sedighi MJ
    Res Pharm Sci; 2017 Apr; 12(2):144-153. PubMed ID: 28515767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness and Cost-Utility Analysis of the Use of Clopidogrel and Pantoprazole in Comparison with Clopidogrel and Omeprazole for the Secondary Prevention of Myocardial Infarction in Iran.
    Amirsadri M; Hajhashemi V; Asemi AS
    J Res Pharm Pract; 2021; 10(2):90-95. PubMed ID: 34527614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness and cost-utility analysis of type-2 diabetes screening in pharmacies in Iran.
    Amirsadri M; Torkpour E
    Res Pharm Sci; 2023 Apr; 18(2):210-218. PubMed ID: 36873274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis.
    Greving JP; Visseren FL; de Wit GA; Algra A
    BMJ; 2011 Mar; 342():d1672. PubMed ID: 21450800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of high, moderate and low-dose statins in the prevention of vascular events in the Brazilian public health system.
    Ribeiro RA; Duncan BB; Ziegelmann PK; Stella SF; Vieira JL; Restelatto LM; Polanczyk CA
    Arq Bras Cardiol; 2015 Jan; 104(1):32-44. PubMed ID: 25409878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-benefit analysis of the polypill in the primary prevention of myocardial infarction and stroke.
    Wald NJ; Luteijn JM; Morris JK; Taylor D; Oppenheimer P
    Eur J Epidemiol; 2016 Apr; 31(4):415-26. PubMed ID: 26946426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease.
    Pandya A; Sy S; Cho S; Weinstein MC; Gaziano TA
    JAMA; 2015 Jul; 314(2):142-50. PubMed ID: 26172894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct healthcare costs and cost-effectiveness of acute coronary syndrome secondary prevention with ticagrelor compared to clopidogrel: economic evaluation from the public payer's perspective in Poland based on the PLATO trial results.
    Pawęska J; Macioch T; Perkowski P; Budaj A; Niewada M
    Kardiol Pol; 2014; 72(9):823-30. PubMed ID: 24846362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of atorvastatin over the product life cycle in the United States.
    Grabner M; Johnson W; Abdulhalim AM; Kuznik A; Mullins CD
    Clin Ther; 2011 Oct; 33(10):1433-43. PubMed ID: 21955936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease.
    Lamotte M; Annemans L; Evers T; Kubin M
    Pharmacoeconomics; 2006; 24(2):155-69. PubMed ID: 16460136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease.
    Chan PS; Nallamothu BK; Gurm HS; Hayward RA; Vijan S
    Circulation; 2007 May; 115(18):2398-409. PubMed ID: 17452609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients with myocardial infarction.
    Ganz DA; Kuntz KM; Jacobson GA; Avorn J
    Ann Intern Med; 2000 May; 132(10):780-7. PubMed ID: 10819700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease.
    Erickson KF; Japa S; Owens DK; Chertow GM; Garber AM; Goldhaber-Fiebert JD
    J Am Coll Cardiol; 2013 Mar; 61(12):1250-8. PubMed ID: 23500327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.